Mucormycosis: The black fungus
DOI:
https://doi.org/10.66344/jpad.v31i4.1880References
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India Diabetes. Metab Syndr.2021;15(4): 102146. doi:10.1016/j.dsx.2021.05.019
2. Rahman T, Hossain MG , Huq AKM , Farzana S , Nazir KHMNH. Mucormycosis (black fungus) in COVID-19 patients-Will it be another matter of concern in the midst of the COVID-19 flare-up in Bangladesh? J Adv Vet Anim Res.2021;8(3):367-9.
3. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med.2021; 9(8):e77.
doi: 10.1016/S2213-2600(21)00265-4.
4. Skiada A, Pavleas I, Apiranthitou MD. Epidemiology and Diagnosis of Mucormycosis: An Update. J Fungi.2020; 6(4):265.
5. Challa S. Mucormycosis: Pathogenesis and Pathology. Curr Fungal Infect Rep.2019; 13(1):11–20.
6. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SCA. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect.2019;25(1):26–34.
7. Available at: https://www.medicinenet.com/mucormycosis/article.htm
8. Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. Journal de Mycologie Medicale.2020;30(3):101007. doi: 10.1016/j.mycmed.2020.101007.
9. Damasceno BPGL, Dominici VA, Urbano IA, et al. Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product. J Biomed Nanotechnol.2012;8(2):290-300.
10. Araújo GMF, Barros AFA, Oshiro JA, Soares LF, Rocha LG, Lima AAN, da Silva JA et al. Nanoemulsions Loaded with Amphotericin B: Development, Characterization and Leishmanicidal Activity. Curr Pharm Des.2019;25(14): 1616-22.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Mahwish Zahoor, Shehla Shaukat, Amina Afzal, Ijaz Hussain
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
